STATEMENT OF MEDICAL NECESSITY (SMN)

Valcyte® (valganciclovir HCI) tablets and for oral solution

Please write legibly and complete all required fields (*) to prevent delays.

Phone: (888) 754-7651 Fax: (800) 305-1830

M-US-00001755(v2.0) 6/21

SERVICES REQUESTED* (check only those that apply) GATCF [†] Patient Assistance Co-pay Assistance							
PATIENT	Last name*: Street: Home phone: () Alternate contact last name: Relationship to patient:	Work/	City: cell phone: (First name:)	State*: Email: Phone: (ZIP:	
INSURANCE	☐ HMO/EPO ☐ PPO☐ Medicare/Medicaid ☐ PBM☐ No insurance Insurance denial/non-coverage po Primary insurance (PI) name: PI phone: PI subscriber name: PI subscriber ID #: Policy/group #: Insurance card attached? ☐ Yes	□ Other:	es	HMO/EPO Medicare/Medicaid No insurance surance denial/non-covecondary insurance (SI) phone: subscriber name: subscriber ID #: blicy/group #: surance card attached?] PBM □ Oth erage policy atta name:	er:Yes	□ No
DIAGNOSIS/TREATMENT	DIAGNOSIS CODE (highest level of specificity)*: \[\text{Z94.0 Kidney transplant status} \text{B20/B25.8/H30.89} \] \[\text{Z94.1 Heart transplant status} \text{CMV retinitis treatment/AIDS (complete 6th digit to specify laterality)} \] \[\text{Z94.0/Z94.83 Kidney-pancreas transplant} \text{Other diagnosis code(s):} \] \[\text{Has patient received transplant?} \text{						
CONTACT & SHIPPING	IS PATIENT CURRENTLY IN A HOSPITAL AWAITING A TRANSPLANT?						
RESCRIPTION	DISPENSE VALCYTE® (valganciclovir HC) (check 1 box in each colum	ın):	□ 90-day supply	Refill	times apy: □ 100 days □	∃ 200 days
PRESCRIBER	Practice name:			First name*: Specialty: State*: ZIP*: () State license #*: PTAN§: First name: Fax: ()			
	UNAPPROVED USE WARNING: Please read the FDA-approved label for Valcyte before prescribing. If the indication for which you are prescribing Valcyte is not listed in the label, you are prescribing Valcyte for an "unapproved" use. The fact that the use for which you are prescribing Valcyte is not listed in the FDA-approved label indicates that the FDA has not approved the efficacy, dosage amount or safety of Valcyte when used for such a use. Nevertheless, GATCF will consider providing Valcyte for your patient with this admonition, based upon your medical order, within program requirements. By signing below, I am agreeing to the following: (A) The Genentech medicine listed above is medically necessary for this patient. (B) I have received authorization to release the information above and other protected health information (as defined by HIPAA) to the Genentech Access to Care Foundation and its affiliates. (C) I will not seek reimbursement for free product provided to the patient. (D) My patient meets the criteria for the Genentech Access to Care Foundation. (E) I understand that Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted. (F) For insured patients, I understand that the Genentech Access to Care Foundation does not provide free drug in the instance of an administrative error or a coverage restriction such as a step edit. For certain products where the step edit may not be medically appropriate, as confirmed by the prescribing physician, the Genentech Access to Care Foundation may consider support following 1 level of appeal. (G) For prescribers in states with official prescription form requirements, such as New York, prescriptions must be submitted on an official state prescription pad along with this enrollment form.						
Sign and date here Prescriber's Signature*: Date*: Date*:							

STATEMENT OF MEDICAL NECESSITY (SMN)

Please write legibly and complete all required fields (*) to prevent delays.

SERVICES REQUESTED

• Check the appropriate services requested on behalf of the patient. GATCF cannot perform services without your specific request

DIAGNOSIS/TREATMENT

- Enter the appropriate Diagnosis Code to the highest level of specificity
- If selecting the ICD-10-CM code for CMV retinitis treatment/AIDS, complete the 6th digit to specify laterality

CONTACT & SHIPPING

- If patient is awaiting transplant, please indicate the transplant coordinator contact information
- Identify the primary contact (transplant coordinator or physician)

PRESCRIPTION

Complete the dose and refill fields along with the dispense instructions

PRESCRIBER

Stamped prescription signatures are not accepted

REQUIRED FIELDS

- All required fields are indicated with an asterisk (*)
- GATCF cannot process your SMN unless these fields are completed

ATTACH TO COMPLETED SMN

 Attach a signed and dated Patient Authorization and Notice of Release for Transmission of Health Information (PAN) form to Genentech Access Solutions and GATCF. GATCF cannot work on your patient's behalf without a signed and dated PAN form

PROVIDING ADDITIONAL DOCUMENTS OR INFORMATION WITH THIS FORM, OTHER THAN WHAT IS REQUESTED, WILL DELAY PROCESSING.

REMINDER: This form cannot be processed without a prescriber's signature and date, as well as a signed and dated PAN form.

Phone: (888) 754-7651 Fax: (800) 305-1830 Valcyte® (valganciclovir HCl) tablets and for oral solution